O'Kane Kieran 4
4 · BIODESIX INC · Filed Nov 13, 2025
Insider Transaction Report
Form 4
BIODESIX INCBDSX
O'Kane Kieran
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-11-10$7.62/sh−25$191→ 7,362 total - Exercise/Conversion
Common Stock
2025-11-10+75→ 7,387 total - Exercise/Conversion
Restricted Stock Units
2025-11-10−75→ 73 total→ Common Stock (75 underlying)
Footnotes (5)
- [F1]These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").
- [F2]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F3]Includes 309 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025.
- [F4]These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
- [F5]These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.